Upstream Bio, Inc. (UPB) Stock Price & Analysis
Upstream Bio, Inc. (UPB) fell 1.15% to USD 6.01 as of September 8, 2026 at 05:48 UTC, according to Nexqual real-time market data.
UPB last closed at USD 6.01; the session ranged USD 5.97–6.23 on volume of 643,266 shares. Market capitalization is —, with a 52-week range of USD 5.77–33.68 (NMS). Source: Nexqual, September 8, 2026 at 05:48 UTC.
Key Statistics (as of September 8, 2026 at 05:48 UTC)
| Price | USD 6.01 |
|---|---|
| Change | ▼ 1.15% (down) |
| Previous Close | USD 6.01 |
| Open | USD 6.01 |
| Day Range | USD 5.97 – 6.23 |
| 52-Week Range | USD 5.77 – 33.68 |
| Volume | 643,266 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (UPB)
Nexqual's technical model rates UPB "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.96 (neutral) |
| vs SMA50 | Below (USD 6.93) |
| MACD | -0.17 (negative) |
From Upstream Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Approximately 350 million people live with asthma around the world, including more than 25 million Americans.
- The major asthma markets, including the United States, France, Spain, Germany, Italy, the United Kingdom ("UK") and Japan, have estimated annual sales of approximately $7.5 billion for 2023 with a compound annual growth rate ("CAGR") of approximately 5.9% through 2032.
- Tezepelumab is projected to reach peak global annual sales of over $3.0 billion for severe asthma alone in 2032, and had achieved more than 20% of new to brand share of prescriptions in the United States in its first commercial year.   12   Taken together, we believe the strength of the biologic market has demonstrated there is room for multiple entrants into the market and the opportunity for rapid acceleration for market share.
- Our team     6   We have built a team with deep experience and a strong track record of execution.
Partnerships
- Dupilumab alone has an annual global sales estimate for the treatment of CRSwNP of up to $1.5 billion by 2030 according to third-party research analyst reports.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | USD 23.17 | ▼ 1.66% |
| MBX | MBX Biosciences, Inc. | USD 61.72 | ▲ 1.36% |
| ZBIO | Zenas BioPharma, Inc. | USD 32.88 | ▼ 0.75% |
| RAPP | Rapport Therapeutics, Inc. | USD 45.77 | ▼ 6% |
| SEPN | Septerna, Inc. | USD 36.75 | ▼ 2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:48 UTC. This page is informational and not investment advice.